Characterization of protein-adjuvant coencapsulation in microparticles for vaccine delivery

• Coencapsulation of protein and peptide-derived adjuvant in vaccine microparticles.
• Methodology for individual isolation and quantification reported.
• Coloading can strongly reduce the encapsulation efficiency of one of the components.
• Establishing correct dose–response relationships demand individual quantification.

Protein antigens encapsulated as vaccines in poly[(rac-lactide)-co-glycolide] (PLGA) microparticle carriers can induce immune responses. The intensity and directions of this response can be controlled by coloading the microparticles with immunomodulatory adjuvants, e.g., muramyl dipeptide (MDP) as adjuvant combined with ovalbumin (Ova) as protein antigen. In this study, methodologies for an individual quantification of both encapsulated substances should be reported, which comprise (i) a separation process to isolate and determine MDP as intact molecule and (ii) a simultaneous degradation of both analytes with subsequent specific quantification of Ova fragments. It was shown that coloading of both substances resulted in a substantially reduced encapsulation efficiency of MDP. This illustrates that correct conclusions on dose–response relationships in future vaccination studies can only be drawn, if a selective method for adjuvant and protein quantification will be applied.

Figure optionsDownload high-quality image (111 K)Download as PowerPoint slide